Scientific Reports (Oct 2024)

Characterization of Collaborative Cross mouse founder strain CAST/EiJ as a novel model for lethal COVID-19

  • Candice N. Baker,
  • Debra Duso,
  • Nagarama Kothapalli,
  • Tricia Hart,
  • Sean Casey,
  • Tres Cookenham,
  • Larry Kummer,
  • Janine Hvizdos,
  • Kathleen Lanzer,
  • Purva Vats,
  • Priya Shanbhag,
  • Isaac Bell,
  • Mike Tighe,
  • Kelsey Travis,
  • Frank Szaba,
  • Jeffrey M. Harder,
  • Olivia Bedard,
  • Natalie Oberding,
  • Jerrold M. Ward,
  • Mark D. Adams,
  • Cathleen Lutz,
  • Shelton S. Bradrick,
  • William W. Reiley,
  • Nadia A. Rosenthal

DOI
https://doi.org/10.1038/s41598-024-77087-1
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Mutations in SARS-CoV-2 variants of concern (VOCs) have expanded the viral host range beyond primates, and a few other mammals, to mice, affording the opportunity to exploit genetically diverse mouse panels to model the broad spectrum of responses to infection in patient populations. Here we surveyed responses to VOC infection in genetically diverse Collaborative Cross (CC) founder strains. Infection of wild-derived CC founder strains produced a broad range of viral burden, disease susceptibility and survival, whereas most other strains were resistant to disease despite measurable lung viral titers. In particular, CAST/EiJ, a wild-derived strain, developed high lung viral burdens, more severe lung pathology than seen in other CC strains, and a dysregulated cytokine profile resulting in morbidity and mortality. These inbred mouse strains may serve as a valuable platform to evaluate therapeutic countermeasures against severe COVID-19 and other coronavirus pandemics in the future.